We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amryt Pharma Plc | LSE:AMYT | London | Ordinary Share | GB00BKLTQ412 | ORD 6P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 143.00 | 151.00 | 170.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/12/2018 21:09 | Just the large trade followed by a series of 20k,20k,15k,50k,25k within a few hours then stops as soon as the prices goes up. Bear in mind Bazworth AMYT has been very thinly traded in recent times. I'm only guessing though so who knows. Perhaps it's a one off trade from someone looking for circa 300k shares but we'll see over the coming days! | greendragon777 | |
04/12/2018 20:49 | greendragon777, what pattern are you referring to? I cannot immediately see what you mean. I suspect there are folk who are ‘gambling̵ Cheers! | bazworth | |
04/12/2018 20:39 | A series of buys today that appear to me to be a single buyer given the pattern. When the price rose the buying stopped so if there's a repeat of this tomorrow and subsequent days then we could have a decent sized investor coming in. Things should start to get interesting around here very soon! 😃 | greendragon777 | |
04/12/2018 15:07 | Interesting post on the lse by that knowledgeable poster, Diamondstar. Diamondstar Posts: 56 Opinion: No Opinion Price: 12.975 RE: No delay in EASE interims Today 14:12 Hi Cookie45, As with most Interim results, you will not be provided with the granular results i.e. Wound Closure at D45 - as the knowledge of the efficacy results can affect the integrity of the trial. For example, if the results show a 20% improvement in wound healing, then existing patients may decide to abandon treatment if they do not see the marked improvement. Hence, the main goal of the interims is to inform of 3 possible outcomes 1) Continue study 'as is' 2) Increase study sample size 3) Discontinue study due to futility. This stop/continue decision will be made by the Data Safety Monitoring Board (DSBM) and will be based both on efficacy and safety data from half of the study population (n=96). >>>>> So, gentlemen place your bets! There are 3 possible outcomes according to Diamondstar: 1/ Everything is hunky-dory and the EASE phase III trial continues: 2/ There are question marks and it's recommended that the EASE phase III trial sample size be increased: 3/ It's futile to continue with EASE phase III trial 1/ is great news, 2/ is bad news, 3/ is shockingly bad news! | papillon | |
04/12/2018 14:45 | Strong start by NVLN (Novelion) on Nasdaq today. Currently up 57.13%. The 3rd wave of the current Elliot Wave Cycle has started as I prophesised. PS. If we get good news on AMYT I will be watching out for the Elliot Waves. EDIT. NVLN currently up 40.82%. Will this 3rd Wave peter out out, or will it re-test November's high? | papillon | |
04/12/2018 13:30 | 5 trades so far today. All buys. See the 5 trades and order depth on this link: PS Another buy for 25k just gone through @ 13.26p. Not showing yet on the link above (there's a 15 min delay) | papillon | |
04/12/2018 13:21 | Well Alan Harris still has his 8.869m (3.23%) of AMYT shares, despite that fibber, Bronxville, on the lse bb going on for over 6 months that he was expecting Harris to sell at any moment! Of course he could do so because his lock in period expired earlier this year, but he hasn't done so even though Cathal Friel managed to find an institutional buyer for 8.38m of his shares (around 25% of his holding at the time)! I wonder why? Perhaps, unlike Bronxville, he sees AMYT as a good investment! Sometime this month we shall see whether Alan Harris has been wise to hang onto his AMYT shares. | papillon | |
04/12/2018 13:05 | sp creeping up. 50k just bought at 13.17p. Don't think it means anything. Just punters buying gambling on good news soon. Though I suppose some could know that an RNS is imminent even if they don't know the contents. | papillon | |
04/12/2018 11:58 | Nice one Paps, well spotted. Hopefully that marks the start of the buying ahead of what we hope will be very positive news! 😃 | greendragon777 | |
04/12/2018 11:40 | Someone bought 156,509 shares @ full asking price (12.80p) very early this morning. Not showing on the lse site. | papillon | |
04/12/2018 11:32 | PMSL. So you're telling me that AMYT is a possible dog and then you start RAMPING a lot of other potential dogs, one of which, REDT, isn't listed and most with awful one year charts that are far worse than that of AMYT! Companies I know NOTHING about and two very speculative oilies that I do know of, but wouldn't touch with a barge pole! ROFLMAO. | papillon | |
03/12/2018 21:40 | I'm only down 20%, MADloss, on paper on AMYT and have only spent around £6k. Just THREE shares bought in the last 3-4 years for a total cost of £8k. On LOGP (£1k) I made £1k profit within 6 months and PVR (£1k) I made £600 profit in less than 6 months. So you could be right, MADloss. I am "smart"! LOL. | papillon | |
03/12/2018 18:31 | More on NFX: “The company takes old drugs cast off by major pharmaceutical companies, works its magic (‘repurposes&r NFX has a comletely different modus operandi to AMYT and you know it MADloss. | papillon | |
03/12/2018 14:57 | Mostly sells again so far today. 4 x 10k and a 20k. All sells @ 12.42p. Readers of Bronxville's posts on the lse bb? LOL. Bronxville's posts should carry a government health warning ..... "Reading Bronxville's posts can seriously damage your wealth!" LOL. | papillon | |
03/12/2018 14:36 | "The EASE trial will be conducted in several countries, and about 164 participants are expected to enroll. Supported by preliminary EASE trial data and nonclinical study results, Amryt Pharma is planning to submit an investigational new drug (IND) application for AP101 with the U.S. Food and Drug Administration. This is expected to allow Amryt to open U.S. trial sites in the third quarter of 2018, in addition to the currently indicated 28 sites in Europe, Australia, Israel, and South America where the EASE trial is being conducted." >>>>> As the above link, dated 21/3/2018, shows the EASE trial, for which we are currently expecting the interim analysis to be issued this month, is only taking place in Europe, Australia, Israel and South America. The USA trial is being conducted separately from the EASE trial and has only recently started. Bronxville knows this of course, but it supports his agenda to disregard it. Why? Because he gets great pleasure out of being contrary. He reminds me of Mr Frankland, the character in Conan Doyle's The Hound of the Baskervilles, with a chip on his shoulder who gets great pleasure out suing all and sundry. A comic character! | papillon | |
03/12/2018 14:10 | More from Bronxville on the lse bb: Bronxville Posts: 645 Opinion: No Opinion Price: 12.60 Another delay? Sun 23:30 Most Recent Events 07 Nov 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Dec 2018. >>>>> To the best of my knowledge this is yet another attempt by Bronxville at being economical with the truth. To the best of my knowledge this information relates only to the clinical studies in the USA which have only recently received approval to be started as announced by AMYT in the 10th September RNS. To the best of my knowledge "an interim efficacy data readout is expected in later 2018 and the top-line data readout is expected in Q2 2019." as announced in the RNS dated 2nd August. You know I get the impression that Bronxville spends hours trawling the web looking for links that he can then use to discredit AMYT by twisting the information contained in those links to suit his agenda. He does the same on the lse PVR bb. He's the ultimate conspiracy theorist. I've no problem with that, but I do find his twisting of facts and economy with the truth annoying. Not that it matters to me because I generally ignore his deramping posts and even if he managed to depress the share price by causing some shareholders to panic and sell their AMYT shares that's not my problem because ultimately AMYT is news driven and by that I mean real news, ie RNS's and not Bronxville's posts. | papillon | |
03/12/2018 13:14 | What on earth are you saying about Spam??!! I love the stuff, but only once or twice a year....!!! Spam, fried eggs and home cooked chips is an unbeatable combo! Once a peasant, always a peasant! In the meantime, we sit back and wait with patience! | bazworth |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions